Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer
Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas
Nexavar Improves PFS In Phase III Trial
Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease
Ibrutinib Produces 68% Overall Response Rate in Phase II Trial
Researchers Uncover Tumors Sensitive to Chemotherapy
Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment
Existing HER2 Drugs May Help More In Breast Cancer Treatment
Smoking Intensity and Markers Predict Cancer Aggressiveness
Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk
No Difference in Toxicity Between IMRT and PRT In Medicare Patients
NCI CTEP Approved Trials For the Month of January
FDA Expands Gleevec Indication For Children with Ph+ ALL
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- ASCO & The Conquer Cancer Foundation announce merit awards
- CBER Director Vinay Prasad dared to “say no to drugs”
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”
